Related Experiment Videos
Moclobemide in social phobia: a controlled dose-response trial
R Noyes1, G Moroz, J R Davidson
1University of Iowa College of Medicine, Iowa City 52242-1000, USA.
Journal of Clinical Psychopharmacology
|August 1, 1997
Summary
Moclobemide, a reversible monoamine oxidase inhibitor, was studied for social phobia. This trial found moclobemide did not demonstrate efficacy compared to placebo after 12 weeks of treatment.
Area of Science:
- Psychopharmacology
- Clinical Psychiatry
- Neuroscience
Background:
- Phenelzine, a monoamine oxidase inhibitor, is effective for social phobia but carries risks.
- Reversible inhibitors like moclobemide offer a potentially safer alternative, but their efficacy for social phobia is unproven.
Purpose of the Study:
- To assess the efficacy and safety of fixed doses of moclobemide in treating social phobia.
- To conduct a double-blind, placebo-controlled investigation into moclobemide's effectiveness.
Main Methods:
- A 12-week, double-blind, placebo-controlled study involving subjects diagnosed with social phobia.
- Random assignment to placebo or one of five fixed daily doses of moclobemide (75, 150, 300, 600, or 900 mg).
- Evaluation of treatment response at 12 weeks.
Main Results:
- No significant differences in treatment response were observed between moclobemide doses and placebo at the 12-week endpoint.
- A trend towards greater efficacy with higher moclobemide doses was noted at 8 weeks but not sustained.
- Moclobemide was generally well-tolerated, with insomnia as the only dose-related adverse event.
Conclusions:
- Moclobemide did not demonstrate statistically significant efficacy in treating social phobia in this dose-response trial.
- Findings contrast with some other studies suggesting efficacy for moclobemide and brofaromine in social phobia.
- Further research is needed to reconcile inconsistent findings regarding reversible monoamine oxidase inhibitors for social phobia.